Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | MOGAT2 | Q3SYC2 | 4/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566403 | 0.93 | FAAH (0.51) | ESR1ESR2FAAHS1PR1MOGAT2 | |
| SCHEMBL3540135 | 0.79 | ESR1 (0.53) | ESR1ESR2ABHD6 | |
| SCHEMBL566294 | 0.79 | ESR1 (0.53) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL31173327 | 0.79 | ESR2 (0.57) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL14677183 | 0.78 | ESR2 (0.59) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL2333879 | 0.77 | ESR1 (0.62) | ESR1ESR2FAAHHDAC8HDAC6 | |
| SCHEMBL4728102 | 0.77 | ESR1 (0.45) | ESR1ESR2FAAHS1PR1HDAC8 | |
| SCHEMBL13650396 | 0.76 | ESR1 (0.68) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL22070855 | 0.76 | ESR1 (0.68) | ESR1ESR2HDAC8HDAC6ABHD6 | |
| SCHEMBL3060013 | 0.76 | ESR1 (0.61) | ESR1ESR2FAAHHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | ESR1 1004/4885ESR2 958/4885FAAH 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.